Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

May 24, 2018 Webinar FAQ: Humanized PDX Models in Immuno-Oncology Patient-derived xenografts (PDX) support highly translational preclinical oncology research, but were historically ill-suited for the assessment of most immunotherapeutics. Humanized PDX models bridge this gap by enabling immuno-oncology (I/O) studies in the context of a functional immune system. LEARN MORE
May 22, 2018 Immuno-Oncology and the Microbiome at AACR 2018 CrownBio presented thirteen posters at AACR 2018, sharing our latest internal research into patient derived xenografts, ... LEARN MORE
May 17, 2018 Genetically Engineered or Syngeneic Mouse Models? Mouse models are a mainstay of preclinical cancer research, and immunocompetent model use is rising with continued ... LEARN MORE
May 15, 2018 Murine Homograft Tumor Models at AACR 2018 We presented a wide range of immuno-oncology model data at AACR 2018, with three of our thirteen posters covering our ... LEARN MORE
May 10, 2018 In Vitro and Ex Vivo Assay Platforms at AACR 2018 We presented a wide range of oncology modelling capabilities at AACR 2018, spanning the breadth of preclinical ... LEARN MORE
May 8, 2018 Latest Data on PDX Models at AACR 2018 We presented the latest data on our PDX models at this year’s AACR Annual Meeting in Chicago, with new studies on DLBCL ... LEARN MORE
May 3, 2018 Humanized Mouse Model Posters at AACR 2018 CrownBio presented thirteen posters at AACR 2018, showcasing a wide range of our oncology and immuno-oncology platforms. This blog post recaps two posters we presented on using humanized mouse models to tackle immuno-oncology problems – specifically a CD3E transgenic mouse model for bispecific antibody testing and PBMC-humanized models for targeted cancer ... LEARN MORE
April 27, 2018 Understanding Cancer Progression and Metastasis “Cancer progression” is the process by which this disease goes from bad to worse. Molecularly, the course of cancer ... LEARN MORE
April 20, 2018 Preclinical Assessment of Osimertinib for NSCLC with EGFR Exon 20 Insertions NSCLC patients with EGFR exon 20 insertions lack treatment options, partly due to a lack of patient genotype-relevant ... LEARN MORE
April 13, 2018 The Establishment and Characterization of PDX Models Patient-derived xenograft models (PDX) support more predictive, clinically-representative in vivo oncology studies than ... LEARN MORE
April 5, 2018 The Limits of In Vitro and Ex Vivo Immuno-Oncology Assays Studying the immune system in vivo can be challenging, and in vitro and ex vivo assays are often used to reduce system complexity. This post looks at the types of I/O assays available, the data they provide, and the caveats to their use in immuno-oncology drug discovery. LEARN MORE
March 22, 2018 Are There Are Five Types of Diabetes? New research suggests that there are five types of diabetes, rather than simply Type 1 or Type 2. Understanding ... LEARN MORE
March 19, 2018 Targeting Myeloid Derived Suppressor Cells in Immuno-Oncology Immune checkpoint inhibitors (ICIs) have dramatically changed the therapeutic approach to cancer, with antibodies ... LEARN MORE
March 13, 2018 ICOS: Immunostimulatory or Immunosuppressive Target? The rise of immunotherapy has brought many new targets to the forefront of oncology drug development. One promising new ... LEARN MORE
March 7, 2018 New Technique Opens Novel Approaches to Insulin Resistance A newly-described technique could open multiple lines of investigation into the pathophysiology and treatment of ... LEARN MORE